Novacyt AI Stock Analysis
Want to see FR:ALNOV full AI Analyst Report?
Novacyt (ALNOV) AI Stock Analysis
Novacyt
(Paris:ALNOV)
The score is held down primarily by weak financial performance—persistent large losses, multi-year cash burn, and rising balance-sheet pressure—despite improving revenue and gross margin. Technicals are neutral-to-soft with only modest support from longer-term averages. The latest earnings call adds some upside via continued revenue growth, a long-term Illumina partnership, and restructuring guidance toward lower cash burn, but execution and profitability remain the central risks.
Novacyt (ALNOV) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 41.38M
- Dividend Yield
- ―
- Average Volume (3M)
- 230.46K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 0.16
- Revenue Growth
- 10.36%
- EPS Growth
- 29.41%
- Country
- France
- Employees
- 228
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Novacyt Business Overview & Revenue Model
Company Description
Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercializati...
How the Company Makes Money
Novacyt makes money primarily by selling in-vitro diagnostic (IVD) products and related consumables to laboratories, hospitals, and other healthcare/testing customers. Key revenue streams typically include: (1) sales of molecular diagnostic test kits...
Novacyt Earnings Call Summary
The call was predominantly positive. Management highlighted 18% year-on-year revenue growth, three consecutive half-years of growth, broad geographic and product expansion, the Southern Cross contribution, the DPYD launch, the five-year Illumina agreement and substantial operating-cost reductions. The principal negatives were the decline in gross margin to 56%, lower RUO sales, continued EBITDA losses, cash consumption and an incomplete restructuring program. Management characterized the cost actions as on plan and said cash burn should materially decline after restructuring.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said the GBP 4 million cost restructuring is on track, with most of the benefit expected in 2027; at the end of September, around 60 staff released represented around a GBP 2.7 million annual reduction in costs, while nonlabor savings were identified at between GBP 0.5 million and around GBP 700,000, for at least around GBP 3.2 million to GBP 3.4 million of savings expected to start flowing through certainly from 2027 onwards, if not very, very soon over the next couple of weeks. The total stock uplift amount is estimated at around GBP 0.5 million, with all of this expected to be released in the 2026 financial results, and longer term the business still expects to deliver a gross margin of over 60%; underlying cash burn is expected to be materially lower once all the restructuring activities have been completed, with benefits starting in the 2027 financial results. The Illumina agreement is for a 5-year period, and management expects this to be a long-term partnership.
Novacyt Financial Statement Overview
Summary
Despite a strong TTM revenue rebound (~+25.9%) and improved gross margin (~44.6%), the company remains deeply loss-making (TTM net margin ~-102%) with continued negative operating and free cash flow (OCF ~-11.9M; FCF ~-12.2M). Balance sheet pressure is rising via higher leverage (~0.55x debt/equity) and shrinking equity, limiting flexibility until profitability and cash generation improve.
Income Statement
24NegativeBalance Sheet
46NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.76M | 20.40M | 19.63M | 11.58M | 21.04M | 92.60M |
| Gross Profit | 14.62M | 7.89M | 32.07M | 3.73M | 5.75M | 63.50M |
| EBITDA | -5.73M | -8.21M | -9.31M | -18.24M | -15.47M | 43.82M |
| Net Income | -33.55M | -23.31M | -41.76M | -28.29M | -25.73M | -9.73M |
Balance Sheet | ||||||
| Total Assets | 37.47M | 40.28M | 70.63M | 133.81M | 140.90M | 183.70M |
| Cash, Cash Equivalents and Short-Term Investments | 8.88M | 19.14M | 30.46M | 44.06M | 86.98M | 101.75M |
| Total Debt | 10.19M | 10.44M | 11.88M | 13.70M | 872.00K | 1.87M |
| Total Liabilities | 18.85M | 16.94M | 22.75M | 46.57M | 25.68M | 41.88M |
| Stockholders Equity | 18.62M | 23.34M | 47.88M | 87.24M | 115.22M | 141.81M |
Cash Flow | ||||||
| Free Cash Flow | -12.18M | -9.03M | -11.01M | -25.66M | -14.14M | 11.59M |
| Operating Cash Flow | -11.87M | -8.76M | -8.49M | -24.99M | -13.73M | 15.69M |
| Investing Cash Flow | -8.58M | -811.91K | -1.86M | -13.94M | -577.00K | -5.03M |
| Financing Cash Flow | -1.58M | -1.99M | -1.84M | -3.97M | -516.00K | -599.00K |
Novacyt Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALNOV, the sentiment is Positive. The current price of 0.45 is above the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.47, and above the 200-day MA of 0.45, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of 65.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALNOV.
Novacyt Peers Comparison
Overall Rating
FR:ALERS58Neutral
FR:ALIKO46Neutral
FR:ALMKT46Neutral
FR:ALNOV46Neutral
FR:ALMDT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | EUR 259.38M | 37.71 | 3.89% | ― | 6.28% | 204.56% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | EUR 22.89M | -5.31 | -22.49% | ― | 37.28% | 7.83% | |
| 46Neutral | EUR 18.02M | 1.46 | -157.72% | ― | 3.38% | ― | |
| 46Neutral | EUR 32.66M | -0.78 | -159.70% | ― | 10.36% | 29.41% | |
| 43Neutral | EUR 213.68M | -3.54 | 271.64% | ― | 2.16% | -5.26% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALNOV | Novacyt S.A. | 0.45 | 0.02 | 3.45% | |
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.09 | 0.01 | 10.98% | |
| FR:ALERS | Eurobio-Scientific SA | 26.35 | 2.20 | 9.11% | |
| FR:ALDMS | Diagnostic Medical Systems | 0.91 | -0.36 | -28.19% | |
| FR:ALIKO | Ikonisys SA | 1.46 | 0.02 | 1.74% | |
| FR:ALMDT | Median Technologies | 4.28 | 1.35 | 45.83% |
Novacyt Corporate Events
Novacyt Reports October Liquidity Activity and Voting Rights
Novacyt reported that Invest Securities bought 118,300 ordinary shares and sold 67,005 shares under the company’s liquidity contract during October 2026. The activity left Novacyt holding 116,872 shares in treasury at the end of the month, supporting...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026
